Trust & Proof: Paradromics – Signal Evidence & AI Readability

The site avoids common trust theatre traps like unverified testimonial carousels, as evidenced by a review_count of 0 and no trust_theatre_flag. It makes bold claims regarding being ‘industry-leading’ and ‘category-defining’ without providing direct outbound proof_links to third-party benchmarks or peer-reviewed citations within the provided text. While it names prestigious clinical sites like Massachusetts General Hospital, the lack of a direct link to a ClinicalTrials.gov registration number or specific patent numbers creates a minor proof gap. The disclaimer that the device is ‘not available for sale’ is a high-integrity signal that offsets typical marketing fluff.

The proof density is high for a pre-commercial entity, with a significant amount of ‘hard’ evidence provided in the form of hardware measurements. The site lists three specific clinical sites and the exact qualifications required for the Connect-One Study, which serves as a form of procedural proof. The ratio of vague assertions to verifiable technical specs is favorable, though the site would benefit from direct links to its published research papers. The inclusion of the 6-year study duration provides a realistic timeframe that counters ‘get-well-quick’ biotech BS.